Elusys gets $44.9M BARDA order

Elusys Therapeutics Inc. (Pine Brook, N.J.) said it received a $44.9 million order for investigational anthrax therapy Anthim obiltoxaximab from the Biomedical Advanced Research and Development Authority for the U.S. Strategic National Stockpile.

A BLA for Anthim is under FDA review to treat and prevent inhalational anthrax, with a PDUFA date of March 18, 2016. Anthim has Fast Track and Orphan Drug designation from FDA. ...